Mature outcomes and prognostic indices in diffuse large B‐cell lymphoma in Malawi: a prospective cohort
Summary Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamid...
Saved in:
Published in | British journal of haematology Vol. 184; no. 3; pp. 364 - 372 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.02.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 0007-1048 1365-2141 1365-2141 |
DOI | 10.1111/bjh.15625 |
Cover
Abstract | Summary
Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109/l (interquartile range [IQR] 0·062–0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow‐up and the 2‐year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age‐adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource‐limited settings but requires validation. |
---|---|
AbstractList | Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109 /l (interquartile range [IQR] 0·062-0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4-6). No patients were lost to follow-up and the 2-year overall survival was 38% (95% confidence interval 28-49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age-adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource-limited settings but requires validation.Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109 /l (interquartile range [IQR] 0·062-0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4-6). No patients were lost to follow-up and the 2-year overall survival was 38% (95% confidence interval 28-49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age-adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource-limited settings but requires validation. Summary Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109/l (interquartile range [IQR] 0·062–0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow‐up and the 2‐year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age‐adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource‐limited settings but requires validation. Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 10 9 /l (interquartile range [IQR] 0·062–0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow‐up and the 2‐year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age‐adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource‐limited settings but requires validation. Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0.113 cells x 10 9 /l (interquartile range [IQR] 0.062–0.227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow-up And the 2-year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS)≥2 and lactate dehydrogenase (LDH)>2x upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH>2x ULN and PS≥2 performed at least as well as the age-adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource-limited settings but requires validation. Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013-2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty-six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 10 /l (interquartile range [IQR] 0·062-0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4-6). No patients were lost to follow-up and the 2-year overall survival was 38% (95% confidence interval 28-49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age-adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource-limited settings but requires validation. Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective SSA cohorts. Patients aged ≥18 years with DLBCL were enrolled in Malawi 2013–2017. Participants were treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy and concurrent antiretroviral therapy (ART) if positive for human immunodeficiency virus (HIV+). Eighty‐six participants (mean age 47 years, standard deviation 13) were enrolled: 54 (63%) were male and 51 (59%) were HIV+, of whom 34 (67%) were on ART at DLBCL diagnosis. Median CD4 count was 0·113 cells × 109/l (interquartile range [IQR] 0·062–0·227) and 25 (49%) had HIV viral load <400 copies/μl. Participants received median six cycles CHOP (IQR 4–6). No patients were lost to follow‐up and the 2‐year overall survival was 38% (95% confidence interval 28–49). In multivariable analyses, Eastern Cooperative Oncology Group performance status (PS) ≥2 and lactate dehydrogenase (LDH) >2× upper limit of normal (ULN) were associated with mortality. HIV status was not associated with mortality. A simplified prognostic model of LDH >2× ULN and PS ≥2 performed at least as well as the age‐adjusted International Prognostic Index. DLBCL can be successfully treated in SSA and outcomes did not differ by HIV status. A simplified prognostic model prognosticates well and may be easier to use in resource‐limited settings but requires validation. |
Author | Dhungel, Bal M. Tomoka, Tamiwe Mhango, Wilberforce Kampani, Coxcilly Kaimila, Bongani Fedoriw, Yuri Shea, Thomas C. Nyirenda, Ruth Mtangwanika, Asekanadziwa Mulenga, Maurice Painschab, Matthew S. Kasonkanji, Edwards Gopal, Satish Chiyoyola, Sarah Chimzimu, Fred Zuze, Takondwa Nyasosela, Richard Chikasema, Maria Montgomery, Nathan D. Krysiak, Robert Tewete, Blessings |
AuthorAffiliation | 4 --Kamuzu Central Hospital, Lilongwe, Malawi 3 --University of Malawi College of Medicine, Blantyre, Malawi 2 —University of North Carolina, Chapel Hill, United States of America 1 --UNC Project-Malawi, Lilongwe, Malawi |
AuthorAffiliation_xml | – name: 1 --UNC Project-Malawi, Lilongwe, Malawi – name: 3 --University of Malawi College of Medicine, Blantyre, Malawi – name: 4 --Kamuzu Central Hospital, Lilongwe, Malawi – name: 2 —University of North Carolina, Chapel Hill, United States of America |
Author_xml | – sequence: 1 givenname: Matthew S. orcidid: 0000-0001-9175-7436 surname: Painschab fullname: Painschab, Matthew S. email: matthew.painschab@unchealth.unc.edu organization: University of North Carolina – sequence: 2 givenname: Edwards surname: Kasonkanji fullname: Kasonkanji, Edwards organization: UNC Project‐Malawi – sequence: 3 givenname: Takondwa orcidid: 0000-0003-3780-0207 surname: Zuze fullname: Zuze, Takondwa organization: UNC Project‐Malawi – sequence: 4 givenname: Bongani surname: Kaimila fullname: Kaimila, Bongani organization: UNC Project‐Malawi – sequence: 5 givenname: Tamiwe surname: Tomoka fullname: Tomoka, Tamiwe organization: University of Malawi College of Medicine – sequence: 6 givenname: Richard surname: Nyasosela fullname: Nyasosela, Richard organization: Kamuzu Central Hospital – sequence: 7 givenname: Ruth surname: Nyirenda fullname: Nyirenda, Ruth organization: Kamuzu Central Hospital – sequence: 8 givenname: Bal M. surname: Dhungel fullname: Dhungel, Bal M. organization: Kamuzu Central Hospital – sequence: 9 givenname: Maurice surname: Mulenga fullname: Mulenga, Maurice organization: Kamuzu Central Hospital – sequence: 10 givenname: Maria surname: Chikasema fullname: Chikasema, Maria organization: UNC Project‐Malawi – sequence: 11 givenname: Blessings surname: Tewete fullname: Tewete, Blessings organization: UNC Project‐Malawi – sequence: 12 givenname: Asekanadziwa surname: Mtangwanika fullname: Mtangwanika, Asekanadziwa organization: UNC Project‐Malawi – sequence: 13 givenname: Sarah surname: Chiyoyola fullname: Chiyoyola, Sarah organization: UNC Project‐Malawi – sequence: 14 givenname: Wilberforce surname: Mhango fullname: Mhango, Wilberforce organization: UNC Project‐Malawi – sequence: 15 givenname: Fred surname: Chimzimu fullname: Chimzimu, Fred organization: UNC Project‐Malawi – sequence: 16 givenname: Coxcilly surname: Kampani fullname: Kampani, Coxcilly organization: UNC Project‐Malawi – sequence: 17 givenname: Robert surname: Krysiak fullname: Krysiak, Robert organization: UNC Project‐Malawi – sequence: 18 givenname: Thomas C. surname: Shea fullname: Shea, Thomas C. organization: University of North Carolina – sequence: 19 givenname: Nathan D. surname: Montgomery fullname: Montgomery, Nathan D. organization: University of North Carolina – sequence: 20 givenname: Yuri surname: Fedoriw fullname: Fedoriw, Yuri organization: University of North Carolina – sequence: 21 givenname: Satish surname: Gopal fullname: Gopal, Satish organization: University of Malawi College of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30450671$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUhS1URKeFBS-ALLGBRVr_JhkWSLQCCmrFBtaW7dyZ8cixg520mh2PwDPyJDhMqaASeGPJ97tH5_gcoYMQAyD0lJITWs6p2W5OqKyZfIAWlNeyYlTQA7QghDQVJaI9REc5bwmhnEj6CB1yIiSpG7pA7kqPUwIcp9HGHjLWocNDiusQ8-gsdqFztjy7gDu3Wk0ZsNdpDfjsx7fvFrzHftcPm9jrGbnSXt-4V1jPEnkAO7prwDZuYhofo4cr7TM8ub2P0Zd3bz-fX1SXn95_OH9zWVkhuKwoWAAGtTFMsoYaKdjSdtByrlstTCd5x1lTW2aIbI3QNW2XptPd0liubUl4jF7vdYfJ9NBZCGPSXg3J9TrtVNRO_T0JbqPW8VrVXJBG8CLw4lYgxa8T5FH1Ls9RdYA4ZcUolzVvRMMK-vweuo1TCiVeoeq2JaT4LtSzPx3dWfndQgFe7gFbfi0nWN0hlKi5YVUaVr8aLuzpPda6UY8uzmGc_9_GjfOw-7e0Ovt4sd_4Cfe7uSM |
CitedBy_id | crossref_primary_10_3389_fcimb_2024_1340096 crossref_primary_10_1089_pmr_2023_0002 crossref_primary_10_1371_journal_pone_0273408 crossref_primary_10_1038_s41379_020_0506_3 crossref_primary_10_1093_oncolo_oyad157 crossref_primary_10_1155_2024_4619644 crossref_primary_10_1007_s12288_024_01927_3 crossref_primary_10_1200_JGO_19_00059 crossref_primary_10_1016_S2352_3018_20_30118_1 crossref_primary_10_1002_cam4_2631 crossref_primary_10_3389_fmed_2024_1336861 crossref_primary_10_1007_s10552_024_01922_z crossref_primary_10_1111_bjh_16575 crossref_primary_10_1111_bjh_19531 crossref_primary_10_1002_cam4_2710 crossref_primary_10_1016_S2214_109X_21_00261_8 crossref_primary_10_1200_GO_21_00315 crossref_primary_10_1016_S2214_109X_21_00181_9 crossref_primary_10_1007_s40278_019_58494_5 crossref_primary_10_26508_lsa_202101355 crossref_primary_10_1053_j_seminhematol_2023_08_005 crossref_primary_10_1007_s11904_021_00542_5 crossref_primary_10_1111_bjh_16617 crossref_primary_10_1007_s00277_023_05418_9 |
Cites_doi | 10.1097/QAD.0000000000000624 10.1002/ijc.29210 10.1200/JCO.2008.18.7641 10.1093/cid/ciu270 10.1097/QAD.0000000000000133 10.1200/JGO.17.00084 10.1186/1472-6890-9-11 10.1182/blood-2003-05-1545 10.1093/ajcp/aqw118 10.1182/blood-2009-11-253039 10.1016/j.transci.2007.06.002 10.1186/s13027-017-0156-3 10.1002/pbc.26370 10.1182/blood-2010-03-276246 10.1097/QAI.0b013e3182a03e9b 10.1056/NEJM199309303291402 10.1371/journal.pone.0150445 10.1182/blood-2009-08-231613 10.1097/QAD.0000000000001652 10.1093/jnci/djt158 10.1111/j.1365-2141.2011.08772.x 10.1200/JGO.2015.002378 10.12659/AJCR.892883 10.3324/haematol.2014.111112 10.1097/QAI.0b013e31820c011a |
ContentType | Journal Article |
Copyright | 2018 British Society for Haematology and John Wiley & Sons Ltd 2018 British Society for Haematology and John Wiley & Sons Ltd. Copyright © 2019 John Wiley & Sons Ltd |
Copyright_xml | – notice: 2018 British Society for Haematology and John Wiley & Sons Ltd – notice: 2018 British Society for Haematology and John Wiley & Sons Ltd. – notice: Copyright © 2019 John Wiley & Sons Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM |
DOI | 10.1111/bjh.15625 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2141 |
EndPage | 372 |
ExternalDocumentID | PMC6340743 30450671 10_1111_bjh_15625 BJH15625 |
Genre | article Journal Article Observational Study Research Support, N.I.H., Extramural |
GeographicLocations | Malawi |
GeographicLocations_xml | – name: Malawi |
GrantInformation_xml | – fundername: NIH Clinical Center funderid: D43TW009340; K01TW009488; P30CA016086; R21CA180815; U2GPS001965; U54CA190152; UM1CA121947 – fundername: NCI NIH HHS grantid: R21 CA180815 – fundername: NCI NIH HHS grantid: U54 CA190152 – fundername: NCI NIH HHS grantid: L30 CA233709 – fundername: NCI NIH HHS grantid: P20 CA210285 – fundername: NCI NIH HHS grantid: U01 CA121947 – fundername: NCI NIH HHS grantid: UM1 CA121947 – fundername: NCI NIH HHS grantid: P30 CA016086 – fundername: FIC NIH HHS grantid: D43 TW009340 – fundername: FIC NIH HHS grantid: K01 TW009488 |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7T5 H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c4435-1ecee2e6bb25271b5429cde833a8a4bd53d3276c2b058b4a6189bdad9bc3ac013 |
IEDL.DBID | DR2 |
ISSN | 0007-1048 1365-2141 |
IngestDate | Thu Aug 21 18:34:21 EDT 2025 Fri Jul 11 08:56:41 EDT 2025 Sun Jul 13 03:57:13 EDT 2025 Sat Jul 26 01:47:19 EDT 2025 Thu Apr 24 22:56:49 EDT 2025 Tue Jul 01 00:53:39 EDT 2025 Wed Jan 22 16:28:47 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | human immunodeficiency virus sub-Saharan Africa diffuse large B-cell lymphoma chemotherapy prognosis |
Language | English |
License | 2018 British Society for Haematology and John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4435-1ecee2e6bb25271b5429cde833a8a4bd53d3276c2b058b4a6189bdad9bc3ac013 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Collection and assembly of clinical data: Matthew S. Painschab, Edwards Kasonkanji, Takondwa Zuze, Bongani Kaimila, Richard Nyasosela, Ruth Nyirenda, Maria Chikasema, Blessings Tewete, Asekanadziwa Mtanwanika, Sarah Chiyoyola, Wilberforce Mhango, Robert Krysiak Conception and design: Satish Gopal and Thomas C. Shea Accountable for all aspects of the work: All authors Final approval of manuscript: All authors Data analysis and interpretation: Matthew S. Painschab, Satish Gopal AUTHOR CONTRIBUTIONS Collection and assembly of pathological data: Tamiwe Tomoka, Bal M. Dhungel, Maurice Mulenga, Fred Chimzimu, Coxcilly Kampani, Robert Krysiak, Nathan D. Montgomery, Yuri Fedoriw Manuscript writing: Matthew S. Painschab, Satish Gopal |
ORCID | 0000-0003-3780-0207 0000-0001-9175-7436 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.15625 |
PMID | 30450671 |
PQID | 2168800833 |
PQPubID | 36395 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6340743 proquest_miscellaneous_2135637472 proquest_journals_2168800833 pubmed_primary_30450671 crossref_primary_10_1111_bjh_15625 crossref_citationtrail_10_1111_bjh_15625 wiley_primary_10_1111_bjh_15625_BJH15625 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2019 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | British journal of haematology |
PublicationTitleAlternate | Br J Haematol |
PublicationYear | 2019 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | 2017; 64 2015; 16 2004; 103 1993; 329 2017; 3 2005; 90 2013; 105 2013; 64 2016; 146 2011; 56 2014; 28 2009; 27 2011; 154 2007; 37 2016; 11 2017; 31 2015; 29 2018; 4 2010; 116 2015; 136 2010; 115 2017; 12 2014; 59 2009; 9 2017 2014; 99 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 Navarro J.‐T. (e_1_2_8_21_1) 2005; 90 e_1_2_8_11_1 e_1_2_8_12_1 Fedoriw Y. (e_1_2_8_10_1) 2017 |
References_xml | – volume: 64 start-page: 66 year: 2013 end-page: 73 article-title: Treatment outcomes in AIDS‐related diffuse large B‐cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa publication-title: Journal of Acquired Immune Deficiency Syndromes – volume: 29 start-page: 811 year: 2015 end-page: 818 article-title: HIV‐infection impact on clinical‐biological features and outcome of diffuse large B‐cell lymphoma treated with R‐CHOP in the combination antiretroviral therapy era publication-title: AIDS – volume: 59 start-page: 279 year: 2014 end-page: 286 article-title: Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort publication-title: Clinical Infectious Diseases – volume: 4 start-page: 1 year: 2018 end-page: 11 article-title: Impact of HIV infection on the clinical presentation and survival of non‐Hodgkin lymphoma: a prospective observational study from Botswana publication-title: Journal of Global Oncology – volume: 146 start-page: 423 year: 2016 end-page: 430 article-title: Accurate real‐time diagnosis of lymphoproliferative disorders in Malawi through clinicopathologic teleconferences: a model for pathology services in sub‐Saharan Africa publication-title: American Journal of Clinical Pathology – volume: 28 start-page: 689 year: 2014 end-page: 697 article-title: HIV status does not impair the outcome of patients diagnosed with diffuse large B‐cell lymphoma treated with R‐CHOP in the cART era publication-title: AIDS – volume: 31 start-page: 2493 year: 2017 end-page: 2501 article-title: Outcomes for HIV‐associated diffuse large B‐cell lymphoma in the modern combined antiretroviral therapy era publication-title: AIDS – volume: 11 start-page: e0150445 year: 2016 article-title: CHOP chemotherapy for aggressive non‐Hodgkin lymphoma with and without HIV in the antiretroviral therapy era in Malawi publication-title: PLoS ONE – volume: 105 start-page: 1221 year: 2013 end-page: 1229 article-title: Temporal trends in presentation and survival for HIV‐associated lymphoma in the antiretroviral therapy era publication-title: Journal of the National Cancer Institute – volume: 64 start-page: e26370 year: 2017 article-title: Quantifying bias in survival estimates resulting from loss to follow‐up among children with lymphoma in Malawi publication-title: Pediatric Blood & Cancer – volume: 115 start-page: 3008 year: 2010 end-page: 3016 article-title: Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV‐associated B‐cell non‐Hodgkin lymphoma publication-title: Blood – volume: 12 start-page: 45 year: 2017 article-title: Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi publication-title: Infectious Agents and Cancer – volume: 3 start-page: 218 year: 2017 end-page: 226 article-title: Burkitt's lymphoma and B‐cell lymphoma unclassifiable with features intermediate between diffuse large B cell lymphoma and Burkitt's lymphoma in patients with HIV: outcomes in a South African public hospital publication-title: Journal of Global Oncology – volume: 56 start-page: 312 year: 2011 end-page: 319 article-title: Predictors of survival after a diagnosis of non‐Hodgkin lymphoma in a resource‐limited setting: a retrospective study on the impact of HIV infection and its treatment publication-title: Journal of Acquired Immune Deficiency Syndromes – volume: 116 start-page: 2040 year: 2010 end-page: 2045 article-title: Long‐term outcome of patients in the LNH‐98.5 trial, the first randomized study comparing rituximab‐CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte publication-title: Blood – volume: 154 start-page: 696 year: 2011 end-page: 703 article-title: Lymphomas in sub‐Saharan Africa–what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? publication-title: British Journal of Haematology – volume: 90 start-page: 704 year: 2005 end-page: 705 article-title: The prognosis of HIV‐infected patients with diffuse large B‐cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV‐negative patients receiving chemotherapy publication-title: Haematologia – volume: 115 start-page: 3017 year: 2010 end-page: 3024 article-title: The role of tumor histogenesis, FDG‐PET, and short‐course EPOCH with dose‐dense rituximab (SC‐EPOCH‐RR) in HIV‐associated diffuse large B‐cell lymphoma publication-title: Blood – volume: 9 start-page: 11 year: 2009 article-title: Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda publication-title: BMC Clinical Pathology – volume: 99 start-page: 1731 year: 2014 end-page: 1737 article-title: A new prognostic score for AIDS‐related lymphomas in the rituximab‐era publication-title: Haematologica – volume: 16 start-page: 347 year: 2015 end-page: 352 article-title: Spontaneous regression of refractory diffuse large B‐cell lymphoma with improvement in immune status with ART in a patient with HIV: a case report and literature review publication-title: The American Journal of Case Reports – volume: 136 start-page: E359 year: 2015 end-page: E386 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: International Journal of Cancer – volume: 37 start-page: 93 year: 2007 end-page: 102 article-title: A single unit lymphoma experience: outcome in a Cape Town academic centre publication-title: Transfusion and Apheresis Science – volume: 27 start-page: 3480 year: 2009 end-page: 3488 article-title: Dose‐modified oral chemotherapy in the treatment of AIDS‐related non‐Hodgkin's lymphoma in East Africa publication-title: Journal of Clinical Oncology – volume: 103 start-page: 275 year: 2004 end-page: 282 article-title: Confirmation of the molecular classification of diffuse large B‐cell lymphoma by immunohistochemistry using a tissue microarray publication-title: Blood – volume: 329 start-page: 987 year: 1993 end-page: 994 article-title: A predictive model for aggressive non‐Hodgkin's lymphoma publication-title: New England Journal of Medicine – year: 2017 – ident: e_1_2_8_2_1 doi: 10.1097/QAD.0000000000000624 – ident: e_1_2_8_11_1 doi: 10.1002/ijc.29210 – ident: e_1_2_8_19_1 doi: 10.1200/JCO.2008.18.7641 – ident: e_1_2_8_13_1 doi: 10.1093/cid/ciu270 – ident: e_1_2_8_8_1 doi: 10.1097/QAD.0000000000000133 – ident: e_1_2_8_17_1 doi: 10.1200/JGO.17.00084 – ident: e_1_2_8_26_1 doi: 10.1186/1472-6890-9-11 – ident: e_1_2_8_15_1 doi: 10.1182/blood-2003-05-1545 – ident: e_1_2_8_18_1 doi: 10.1093/ajcp/aqw118 – ident: e_1_2_8_9_1 doi: 10.1182/blood-2009-11-253039 – ident: e_1_2_8_28_1 doi: 10.1016/j.transci.2007.06.002 – ident: e_1_2_8_16_1 doi: 10.1186/s13027-017-0156-3 – ident: e_1_2_8_25_1 doi: 10.1002/pbc.26370 – ident: e_1_2_8_7_1 doi: 10.1182/blood-2010-03-276246 – volume: 90 start-page: 704 year: 2005 ident: e_1_2_8_21_1 article-title: The prognosis of HIV‐infected patients with diffuse large B‐cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV‐negative patients receiving chemotherapy publication-title: Haematologia – ident: e_1_2_8_27_1 doi: 10.1097/QAI.0b013e3182a03e9b – ident: e_1_2_8_22_1 doi: 10.1056/NEJM199309303291402 – ident: e_1_2_8_14_1 doi: 10.1371/journal.pone.0150445 – ident: e_1_2_8_24_1 doi: 10.1182/blood-2009-08-231613 – ident: e_1_2_8_5_1 doi: 10.1097/QAD.0000000000001652 – ident: e_1_2_8_12_1 doi: 10.1093/jnci/djt158 – ident: e_1_2_8_20_1 doi: 10.1111/j.1365-2141.2011.08772.x – ident: e_1_2_8_23_1 doi: 10.1200/JGO.2015.002378 – ident: e_1_2_8_6_1 doi: 10.12659/AJCR.892883 – ident: e_1_2_8_3_1 doi: 10.3324/haematol.2014.111112 – ident: e_1_2_8_4_1 doi: 10.1097/QAI.0b013e31820c011a – volume-title: October). Identifying transcription and prognostic biomarkers of HIV‐associated diffuse large B‐cell lymphoma from Malawi year: 2017 ident: e_1_2_8_10_1 |
SSID | ssj0013051 |
Score | 2.410818 |
Snippet | Summary
Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first... Outcomes for diffuse large B‐cell lymphoma (DLBCL) in sub‐Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective... Outcomes for diffuse large B-cell lymphoma (DLBCL) in sub-Saharan Africa (SSA) are poorly described. We report mature data from one of the first prospective... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 364 |
SubjectTerms | Adult Aged Anti-Retroviral Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antiretroviral therapy B-cell lymphoma CD4 antigen Chemotherapy Cyclophosphamide Cyclophosphamide - administration & dosage diffuse large B‐cell lymphoma Disease-Free Survival Doxorubicin Doxorubicin - administration & dosage Hematology HIV HIV Seropositivity - diagnosis HIV Seropositivity - drug therapy HIV Seropositivity - mortality HIV-1 Human immunodeficiency virus Humans L-Lactate dehydrogenase Lactic acid Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Malawi - epidemiology Middle Aged Mortality Oncology Prednisone Prednisone - administration & dosage prognosis Prospective Studies sub‐Saharan Africa Survival Rate Vincristine Vincristine - administration & dosage |
Title | Mature outcomes and prognostic indices in diffuse large B‐cell lymphoma in Malawi: a prospective cohort |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.15625 https://www.ncbi.nlm.nih.gov/pubmed/30450671 https://www.proquest.com/docview/2168800833 https://www.proquest.com/docview/2135637472 https://pubmed.ncbi.nlm.nih.gov/PMC6340743 |
Volume | 184 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0007-1048 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-2141 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013051 providerName: Wiley-Blackwell |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VPVRceD8CBRnEgUtWtR07CT1RRLWqtBwQlXpAimzHUReWBHUTITjxE_iN_SWdcR50KUiIUyJlkjj2zPhzZvwNwHNhbKrySsel0j5OjJRx7jyPvVHS4YqCG027kRdv9fw4OTpRJ1uwP-6F6fkhph9uZBnBX5OBG7u-ZOT24-mME3xH_8ulCiHad-JXBGFPDdXyUnQ1STawClEWz3Tn5lx0BWBezZO8jF_DBHR4Az6MTe_zTj7NutbO3PffWB3_89tuwvUBmLJXvSbdgi1f34adxRB6vwPLRaAAZU3X4tP8mpm6ZJTdVTdE9cwo9o0-B4-Miq50a89WlGXODs5__KTwAFt9Q81pPhsSWZiV-bp8yQw9Ytztyaha71l7F44P37x_PY-HOg2xSxBtxdzjTCu8tlYokXJLJbBc6TMpTWYSWypZSpFqJ-yeymxiNM9yW5oyt04ah0N1D7brpvYPgGUKV6yVq5zzZaITbisvtaykkM4SF14EL8YRK9xAYk61NFbFuJjBritC10XwbBL90jN3_Elodxz2YjDedSG4Rq-G2FRG8HS6jGZHnWVq33QkgyoncS0mIrjfa8n0Fgo-IwjgEaQb-jMJEKX35pV6eRqovbVMCNPhZwb1-HvDi4OjeTh5-O-ij-Aawr28zznfhe32rPOPEVK19kmwnQtpjh-t |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIgGX8ltIKWAQBy5ZNXbsJIgLBaqlND2gVuoFRbbjqAtLUnUTVXDiEXhGnoSZ_NGlICFOieSJ49gz9ufM-BuAp1ybSCaF8nOpnB9qIfzEusB3WgqLO4pAKzqNnO6r6WG4eySPVuDFcBam44cYf7iRZbTzNRk4_ZA-Z-Xm4_EkIPx-CS6Tf47M8vV7_suHsCX7fHkRTjZh3PMKURzP-OjyanQBYl6MlDyPYNslaOc6fBga30WefJo0tZnYr7_xOv7v192AtR6bspedMt2EFVfegitp732_DbO0ZQFlVVNjdW7BdJkzCvAqK2J7ZuT-xmkHr4zyrjQLx-YUaM62f3z7Th4CNv-CylN91iSS6rk-mz1nmqoYDnwySth7Wt-Bw503B6-mfp-qwbchAi4_cLjYcqeM4ZJHgaEsWDZ3sRA61qHJpcgFj5TlZkvGJtQqiBOT6zwxVmiLY7UOq2VVunvAYomb1sIW1rochzUwhRNKFIILa4gOz4Nnw5Bltucxp3Qa82zYz2DXZW3XefBkFD3pyDv-JLQ5jHvW2-8i44HCiQ3hqfDg8ViMlkedpUtXNSQjpBK4HeMe3O3UZHwL-Z8RBwQeREsKNAoQq_dySTk7btm9lQgJ1uFntvrx94Zn27vT9mbj30UfwdXpQbqX7b3df3cfriH6S7oQ9E1YrU8b9wARVm0etob0E0GPI8k |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceFNSChjEgUtWjV-bwIkCq6WwFUJU6gEpsh1HXdgmVTcRghM_gd_IL2EmL7oUJMQpkTJJHHvG_iYz_gbgETd2rJJch5nSPpRGiDBxPgq9UcKhRxEZTbuRZ_t6eiD3DtXhGjzt98K0_BDDDzeyjGa-JgM_yfIzRm4_Ho0igu8X4KLU6F0RInrHf4UQdlRXLm-Mc42MO1ohSuMZbl1djM4hzPOJkmcBbLMCTa7Ah77tbeLJp1Fd2ZH7-hut439-3FW43CFT9qxVpWuw5ovrsDHrYu83YD5rOEBZWVf4NL9kpsgYpXcVJXE9Mwp-46SDR0ZVV-qlZwtKM2e7P759p_gAW3xB1SmPDYnMzMJ8nj9hhh7Rb_dkVK73tLoJB5OX759Pw65QQ-gkwq0w8rjUcq-t5YqPI0s1sFzmYyFMbKTNlMgEH2vH7Y6KrTQ6ihObmSyxThiHQ3UL1ouy8LeBxQpd1tzlzvlMahnZ3AstcsGFs0SGF8DjfsRS17GYUzGNRdp7M9h1adN1ATwcRE9a6o4_CW33w5521rtMeaRxWkNwKgJ4MFxGu6POMoUva5IRSgt0xngAm62WDG-h6DOigCiA8Yr-DALE6b16pZgfNdzeWkgCdfiZjXr8veHp7t60Odn6d9H7sPH2xSR982r_9R24hNAvafPPt2G9Oq39XYRXlb3XmNFPx9IieA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mature+outcomes+and+prognostic+indices+in+diffuse+large+B%E2%80%90cell+lymphoma+in+Malawi%3A+a+prospective+cohort&rft.jtitle=British+journal+of+haematology&rft.au=Painschab%2C+Matthew+S.&rft.au=Kasonkanji%2C+Edwards&rft.au=Zuze%2C+Takondwa&rft.au=Kaimila%2C+Bongani&rft.date=2019-02-01&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=184&rft.issue=3&rft.spage=364&rft.epage=372&rft_id=info:doi/10.1111%2Fbjh.15625&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bjh_15625 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |